Alinity m HCV

FDA Premarket Approval P190025 S006

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

The request tp release the software version 1. 6. 2 in the united states, incorporating into the alinity m system software version 1. 6. 0, version 1. 6. 1 and 1. 6. 2, which are currently released outside, the us, is approved.

DeviceAlinity m HCV
Generic NameAssay, Hybridization And/or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,hepatitis C Virus
ApplicantAbbott Molecular, Inc.
Date Received2021-04-15
Decision Date2021-06-01
PMAP190025
SupplementS006
Advisory CommitteeMicrobiology
Supplement TypeReal-time Process
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address Abbott Molecular, Inc. 1300 E. Touhy Avenue des Plaines, IL 60018

Supplemental Filings

Supplement NumberDateSupplement Type
P190025Original Filing
S006 2021-04-15 Real-time Process
S005 2021-02-05 30-day Notice
S004
S003 2020-12-21 30-day Notice
S002 2020-05-07 30-day Notice
S001 2020-04-06 30-day Notice

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.